Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 951-958

  Lee, Justin M S ^a   Wiesmann, Frank ^a   Shirodaria, Cheerag ^a   Leeson, Paul ^a   Petersen, Steffen E ^a   Francis, Jane M ^a   Jackson, Clare E ^a   Robson, Matthew D ^a   Neubauer, Stefan ^a   Channon, Keith M ^a   Choudhury, Robin P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Aorta; Atherosclerosis; Carotid; Magnetic resonance imaging; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY DISEASE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION;

AGED; AORTA; ATHEROSCLEROSIS; CAROTID ARTERIES; CAROTID STENOSIS; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED;

EID: 40949150179     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.09.001     Document Type: Article

References (46)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
3. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
4. Smilde T.J., van Wissen S., Awollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577
5. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
6. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
7. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 46 (2005) 106
8. Saam T., Yuan C., Chu B., et al. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis (2006) [Epub ahead of print]
9. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
11. Ray K.K., and Cannon C.P. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 18 (2004) 89-101
12. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
13. Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104 (2001) 376-379
14. Vogel R.A., Corretti M.C., and Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 77 (1996) 37
15. Reis E.D., Li J., Fayad Z.A., et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J Vasc Surg 34 (2001) 541-547
16. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
17. Wiesmann F., Petersen S.E., Leeson P.M., et al. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol 44 (2004) 2056-2064
18. Lee J.M., Shirodaria C., Jackson C.E., et al. Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 4 (2007) 44-48
19. Mattace-Raso F.U.S., van der Cammen T.J.M., Hofman A., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 113 (2006) 657-663
20. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
21. Grundy S.M., Cleeman J.I., Merz C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 24 (2004) e149-e161
22. Saam T., Kerwin W.S., Chu B., et al. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J Cardiovasc Magn Reson 7 (2005) 799-808
23. Mani V., Aguiar S.H., Itskovich V.V., et al. Carotid black blood MRI burden of atherosclerotic disease assessment correlates with ultrasound intima-media thickness. J Cardiovasc Magn Reson 8 (2006) 529-534
24. Jackson C., Shirodaria C., Lee J.M.S., et al. Accurate automated measurement of dynamic arterial lumen area by CMR. J Cardiovasc Magn Reson 8 (2006) 260-261
25. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-742
26. Lee J.M.S., and Choudhury R.P. Prospects for atherosclerosis regression: HDL elevation and other emerging therapeutic technologies. Heart 93 5 (2007) 559-564
27. Zhao X.-Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
28. Saam T., Yuan C., Zhao X.Q., et al. Rosuvastatin treatment and its effects on plaque composition of carotid atherosclerosis in moderately hypercholesterolemic subjects: a high-resolution magnetic resonance imaging trial. Atherosclerosis (Suppl.) 6 (2005) 1-201
29. Zhao X.Q., Phan B.A., Chu B., et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition study. Am Heart J 154 (2007) 239-246
30. Sirol M., Itskovich V.V., Mani V., et al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 109 (2004) 2890-2896
31. Yarnykh V.L., Terashima M., Hayes C.E., et al. Multicontrast black-blood MRI of carotid arteries: comparison between 1.5 and 3 T magnetic field strengths. J Magn Reson Imaging 23 (2006) 691-698
32. Ray K.K., and Cannon C.P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. Am J Cardiol 96 (2005) 54F-60F
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. New Engl J Med 352 (2005) 29-38
34. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. New Engl J Med 352 (2005) 20-28
35. Forbat S.M., Naoumova R.P., Sidhu P.S., et al. The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study. J. Cardiovasc. Risk 5 (1998) 1-10
36. Smilde T.J., van den Berkmortel F.W., Wollersheim H., et al. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 30 (2000) 473-480
37. Kool M., Lustermans F., Kragten H., et al. Does lowering of cholesterol levels influence functional properties of large arteries?. Eur J Clin Pharmacol 48 (1995) 217-223
38. Ferrier K.E., Muhlmann M.H., Baguet J.-P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 39 (2002) 1020
39. Neunteufl T., Kostner K., Katzenschlager R., et al. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol 32 (1998) 711-716
40. Sebestjen M., Zegura B., and Keber I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med 251 (2002) 77-85
41. Glagov S., Weisenberg E., Zarins C.K., et al. Compensatory enlargement of human atherosclerotic coronary arteries. New Engl J Med 316 (1987) 1371-1375
42. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New Engl J Med 356 (2007) 1620-1630
43. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. New Engl J Med 356 (2007) 1304-1316
44. Tardif J.-C., Gregoire J., L'Allier P.L., et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110 (2004) 3372-3377
45. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
46. Kathiresan S., Larson M.G., Keyes M.J., et al. Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the distribution of subclinical atherosclerosis across Framingham risk strata. Am J Cardiol 99 (2007) 310-314